Targeted Cancer Diagnostic and Therapeutic Agents: Delivery by Carriers or Conjugation

Mohsen Mohammadgholi 1, Farzaneh Rezazadeh 1, Nourollah Sadeghzadeh 1*

1 Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

Article

Abstract

Receptors and proteins are overexpressed in many human cancer cell membranes rather than normal tissues and are considered as the main molecular targets. Specific tumor- targeting molecules which have high affinity for these receptors can be valuable tools as carrier molecules for targeted cancer therapy and imaging. Pharmacokinetics and bioavailability of diagnostic and therapeutic agents are very important. Poor selectivity of cancer therapeutic agents causes toxicity on normal cells that limits maximum effective dose. The Attachment of these agents to macromolecules or their installation on carriers is currently under investigation. This article presents recent developments in the field of targeting agents and introduces different carriers and their applications in the diagnosis and treatment of cancer.

Keywords: Cancer diagnosis; Cancer therapy; Biological carrier molecules; Diagnostic agent; Therapeutic agents

Introduction

Cancer is still one of the major causes of death worldwide. Generally, surgery, chemotherapy and radiation therapy are used for treatment of cancer. There is a balance between division, senescence and differentiation in the healthy cells, but the difference in malignant cell cycle kinetics and gene expression levels make them very susceptible to bombardment with cell proliferative inhibitors or toxic agents. Similarly, normal cells that rapidly proliferate like malignant cells are highly subject to damage by cytotoxic drugs. Bone marrow, hair follicles, and intestinal epithelium have quick turnover which results in more sensitivity to chemotherapeutic agents. Tumor cells consume glucose more than normal cells but have low efficiency and are hypoxic. Hypoxic cells are resistant to radiation whether externally or internally. One of pathophysiological characteristics of tumors is rapid vascularization with poor lymphatic drainage which makes them accessible for targeting agents (1-3). Enzymes (4, 5), receptors (6, 7) and factors (8, 9) which are more expressed in cancerous cells can be restrained by various inhibitors. Oncogenes can be damaged by DNA cross linkers, resulting in DNA synthesis inhibition and malfunction. Multidrug resistance was also observed in tumor cell population that was exposed to some anticancer drugs. Targeted drug delivery (10), also named smart drug delivery is a method of delivering imaging or therapeutic agents to a patient in a manner that increases the concentration of these agents in some parts of the body compared to others. Several radionuclides can be used to label biomolecules or carrier systems for noninvasive imaging of tumors in single photon emission computed tomography (SPECT) or positron emission tomography camera (PET) (11, 12). Researchers were interested to design $^{99m}$Tc radiolabeled systems with high target to non-target biodistribution ratio, high pictorial resolution, appropriate clearance and pharmacokinetic and simple preparation in imaging centers. In this review article, we describe biological and nanocarrier agents as valuable tools for cancer diagnosis and therapy. We
focus on antibodies, aptamers, polymers, proteins, peptides, nanosystems and aptides.

1. Antibodies
Antibodies can be used as a carrier molecule for the delivery of radioisotopes (1), toxins, enzymes, or drugs into tumor sites (Figure 1). Monoclonal antibody drug conjugation (mADC) is a better strategy to increase the potency of toxic agents with low molecular weight and clinical activity. Linker stability and suitable antigen selection are also important issues in targeting. ADCs showed high intracellular collection through tight binding to tumor-associated cell surface antigens and long circulation time in the plasma. After complex formation and internalization, cytotxic agent releases and finally reaches intracellular target. Nonetheless, only small amount of the ADC have ever reached the target cells (13-16). In 2001, Senter and Springer selectively activated anticancer drugs, by monoclonal antibody-enzyme conjugates. Enzymes catalytically convert prodrugs to active drugs in three steps. MAb-enzyme binds to cell-surface antigens in the first step, then the enzyme activates prodrug to drug and eventually drug enters into cell. Reduction of immunogenicity can be the result of this innovation (17). In 2004, Hamblett, Senter, Chace, et al. studied conjugation of monomethylauristatin E (MMAE) to the anti-CD30 monoclonal antibody with eight drug moieties per mAb. Their investigation proved that the therapeutic index has inverse proportion to drug loading per antibody (18). In 2010, Kuroda et al. conjugated a humanized anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (hJ591) to the ribosome-inactivating protein toxin saporin to generate an immune toxin for treatment of prostate cancer (PC). Both in vivo and in vitro studies demonstrated that anti-PSMA immune toxin acts as a therapeutic agent for PC (19).

![Figure 1. Antibodies can conjugate to radionuclides or chemotherapeutic agents whether directly or with linker assistance](image)

Antibodies have been labeled with various radionuclides (RNs) for cancer treatment, but only two radionuclides (RNs) for cancer treatment. Antibodies have been chemotherapeutic agents whether directly or with linker assistance. In vitro results demonstrated that anti-Cancer (PC). Both in vivo and in vitro studies generate an immune toxin for treatment of prostate cancer (PC). In 2001, Senter and Springer selectively activated anticancer drugs, by monoclonal antibody-enzyme conjugates. Enzymes catalytically convert prodrugs to active drugs in three steps. MAb-enzyme binds to cell-surface antigens in the first step, then the enzyme activates prodrug to drug and eventually drug enters into cell. Reduction of immunogenicity can be the result of this innovation. In 2004, Hamblett, Senter, Chace, et al. studied conjugation of monomethylauristatin E (MMAE) to the anti-CD30 monoclonal antibody with eight drug moieties per mAb. Their investigation proved that the therapeutic index has inverse proportion to drug loading per antibody. In 2010, Kuroda et al. conjugated a humanized anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (hJ591) to the ribosome-inactivating protein toxin saporin to generate an immune toxin for treatment of prostate cancer (PC). Both in vivo and in vitro studies demonstrated that anti-PSMA immune toxin acts as a therapeutic agent for PC.

2. Aptamers
Despite the advantages of antibodies, they have some limitations on clinical use which encouraged the researchers to seek alternatives for antibodies. These limitations include low tissue penetration, immunogenicity, instability and formulation issues, and high manufacturing costs. Antibody-based drug delivery may lead to high toxicity due to nonspecific uptake of antibody by Fc normal receptor-expressing cells. Aptamers are a class of therapeutic oligonucleotides that form special three-dimensional ligand that makes them attractive pharmaceutical agents. They bind to their targets with high affinity and demonstrate therapeutic and imaging effect (23) (Figure 2).

![Figure 2. DNA or RNA aptamers can be labeled with radionuclides directly or through linker that is ended to chelating agents. Chemotherapeutic agents also bind to nucleotide functional groups or linker intercession.](image)

In 2006, Farokhzad and Jon et al. hypothesized that doxorubicin (DOX) may intercalate into the A10 PSMA aptamer and form a physical complex through noncovalent interaction, requiring no modification of the drug or the aptamer. In vitro results displayed stability of the DOX-A10 PSMA aptamer complex in cell culture media and targeted the PSMA-expressing cells with high efficiency. In 2009, Tan et al. explored the usage of drug DNA-based aptamer conjugation for targeted drug therapy applications. They used sg8c aptamer and chose a bifunctional linker to conjugate sg8c to Doxorubicin. Aptamer conjugated DOX showed high specific binding and affinity to target human T-cell. In 2014, Zhao and JianHao, Wei Fan et al. conjugated miR-15a and miR-16-1 aptamers (novel therapeutic ligand against...
PC metastasis) to atelocollagen (purified pepsin-treated type I collagen from the calf dermis) that could selectively cause PC cell death in synergetic action. In vitro studies in PC3 and LNCaP cell lines by IC50 values revealed that cell growth has been inhibited in a dose-dependent manner. In vivo anticancer efficacy was verified in the human PC bone metastasis mice model (26). Moreover aptamers have been labeled with radionuclide for tumor imaging (1). For example in 2006, Hicke et al. labeled aptamerTTA1 with $^{99m}$Tc for malignant tumors imaging (27).

3. Polymers, proteins and peptides

One problem about aptamers is that, they need high expression level of target on the cell lines for efficient internalization. Synthesis of oligonucleotides is expensive and has low yield and also cargo attachment and its optimization need more attention. In addition, there are no clinical data to illustrate feasibility of aptamers’ mediation delivery (22). In recent years, short peptides which can target tumor-specific markers (28-33) and water soluble polymers have been used as vehicles for the delivery of anticancer drugs with low molecular weight to tumor tissues (34) (Figure 3). Long circulation time, resistance to enzymatic degradation and low immunogenicity are benefits of polymeric conjugations. Poly ethylene glycol (PEG) as one of the most widely used polymer is inexpensive and has low toxicity, commercially available in various molecular weights and has been approved for internal applications by drug regulatory methods. PEGylated interferon α-2b and L-asparaginase modified with PEG are two FDA-approved polymeric anticancer drugs.

![Figure 3. Peptides can covalently bind to radiodine through Tyrosine or can bind to $^{99m}$Tc with special sequences directly or indirectly by linkers or chelator conjugation.](image)

Conjugation with poly (styrene-co-maleic acid anhydride) (SMA) increases blood plasma circulation time through binding to albumin and decreases enzymatic degradation and immunogenicity similar to PEG. SMA conjugated neocarzinostatin has been recently approved in Japan for hepatoma treatment. Also dextran a pH sensitive, dryscope and biodegradable polymer has been used in drug delivery (35). In 2006, Chau et al. designed a new dextran-peptide conjugated methotrexate (MTX) to achieve tumor-targeted delivery of MTX. They used two sequences of peptides as a linker between dextran and MTX. Histological studies in animal models demonstrated significant antitumor efficacy, but weight loss as a toxicity indicator was minor (36). Integrins as cell surface receptors to mediate adhesion between cells and the extracellular matrix (ECM), by binding to ligands with exposed arginine-glycine-aspartate (RGD) sequence (cell adhesion motif). In 2010, Wang and Zhang et al. modified DOX-loaded liposome by RGD peptide to improve its anticancer efficacy. Indeed, laser confocal scanning microscopy (LCSM) detection, DOX cellular uptake and distribution have been enhanced by RGD modification in the three cell lines (B16, B16F10 and HUVEC) (37). In 2013, Wu et al. found that SP90 (H2N-SMDPFLFQLLQL-COOH) conjugated liposomal DOX increases the therapeutic index of the DOX by selective accumulation in tumor xenograft compared to normal organs. They concluded that the SP90 has significant potential in the chemotherapy and clinical diagnosis of breast cancer (38). There are many peptides which have been modified selectively to enhance in vivo stability and resistance against proteolytic degradation, especially for tumor cells. They have been labeled with different radionuclides for imaging by PET or SPECT (29). Bombesin (BBN) a neuropeptide with high affinity for gastrin-releasing peptide (GRP) receptors which are overexpressed in prostate, breast, and small-cell lung carcinoma, is
radiolabeled with both $^{99m}$Tc and 18F for prostate cancer imaging (39-41). In 2009, king et al. labeled three improved gastrin peptides with $^{99m}$Tc and their studies proved significant tumor uptake in micebearing AR42J tumor xenograft 1 hour after injection (42). Cyclic RGD is also labeled with $^{99m}$Tc for angiogenesis imaging (43).

4. Nano systems
There are some criteria for a polymer-drug conjugation: 1) biocompatibility and biodegradability of polymers; 2) Hydrophilicity of polymers backbone; 3) Chemical stability in plasma and 4) Low steric hindrance for drug covalent attachment facility and accessibility (38). The nanocarrier surface modification improves their pharmacokinetics, bioavailability, toxicity and customization of formulation (44). Nano systems may be quantum dots (QDs), super paramagnetic iron oxide nanoparticles (SPIONs), nanopolymers or biocompatible nanocarriers such as nanoliposomes which are more attractive for designing anticancer agents and radionuclides targeted delivery (Figure4).

**Figure 4.** A: nanoliposomes encapsulated radioisotopes; B: nanoliposomes encapsulated chemotherapeutic agents; C: radioactive nanoparticles; D: nanoliposomes; and E: nanoparticles modified with cancer diagnostic and therapeutic agents.

Doxil® is DOX encapsulated nanoliposomes commercially available product which is the result of nano systems for targeted drug delivery system (45). Nanoparticles are usually trapped by reticuloendothelial system (RES) depending on their charge, hydrophobicity and size ranges. Particles with size 100 nm or less in diameter and hydrophilic surface cannot be cleared by macrophages thus they have longer circulation time in bloodstream and hence have greater ability to target sites. Paclitaxel as microtubule polymerization stabilizer with severe side effects such as hypersensitive reactions, nephrotoxicity and neurotoxicity when encapsulated with Poly (lactic-co-glycolic) acid (PLGA) is released with very constant rate and over a long period of time (46). DOX, Docetaxel and some anticancer drugs have also been investigated by this controlled delivery (47). Platinum-based anticancer drugs coated with gold nanoparticles were functionalized with a thiolated poly (ethylene glycol) (PEG) monolayer and have been prepared to avoid dose-limiting side effects and possible drug resistance. IC50 in colon cancer cell lines (HCT116, HCT15, HT29, and RKO and human lung cancer cell line A549) exhibited more toxicity compared to oxaliplatin as control (48). Topotecan (TPT), a highly active camptothecin (CPT) and cytotoxic quinoline alkaloid which inhibits the DNA topoisomerase I has been encapsulated in nanoliposomes with acidic interior where the drug can be stabilized in the active lactone configuration. Tumor size decreased in human prostate (DU-145) and breast cancer (BT-474) xenograft models which confirmed in vivo efficacy and reliability of liposomal TPT (49). Nanotargeted radionuclides have also been designed for cancer nuclear imaging and internal radiotherapy. Auger electron, α, β and γ-radiation emitters have been used in chelating by surface modified nanosystems or encapsulating in flexible nanoliposomes (2, 50). Gold-198 ($^{198}$Au) nanoparticles are progressing in oncology and have some advantages due to synergistic molecular imaging and therapy properties. $^{198}$Au is a medium-energy β-emitter ($\beta_{max}=0.96$ MeV; $T_{1/2}=2.7$ days with a $\gamma$-radiation at 0.411 MeV). In 2010, Chanda et al. conjugated BBN peptide to both radioactive and non-radioactive gold nanoparticles (AuNPs). Intraperitoneal injection of modified AuNP-BBN in normal mice showed RES uptake is reduced however, it increased at tumor targets. They also observed a widespread uptake of BBN conjugated $^{198}$AuNPs in GRP-receptor-expressing pancreatic acini with maximum radioactivity after 4 h and slow clearance beyond 12 and 24h (51). Biological evaluation, both biodistribution and scintigraphic for $^{99m}$Tc-nanoliposomes in healthy CD1 mice at 1 and 3 hours post injection demonstrated high liver uptake without pertinent accumulation in other organs (52). In 2004, Bao et al. labeled Pegylated Liposomal DOX with $^{99m}$Tc directly using N, N-bis (2-mercapto-ethyl)-N, N-diethyl-ethylenediamine (BMDA). Scintigraphic images in normal rats with $^{99m}$Tc-Doxil® in comparison with $^{99m}$Tc-BMEDA alone depicted slow blood clearance in RES and the injected activity curve in blood dropped out less than 5 percent within 45 hours (53).

5. Aptides
The design and development of targeting ligand for diagnosis and therapy of human cancers has been investigated for several decades. “Aptides”, from aptamer-like peptides, are composed of a stabilizing scaffold and two target binding regions. The scaffold
Aptides as novel antibody shaped and aptamer like peptides can promise well in targeted drug delivery.

The lack of its tissue specificity, leads to adverse side effects such as hematological toxicity. In vitro and in vivo studies demonstrated that APTEDB conjugated DTX is more effective in cancer therapy of EDB-overexpressing tumors with much lower toxicity than the free drug. Murine LLC and human U373MG cell lines were used as EDB positive and negative cancer cells, respectively. APTEDB- DT X (5mg DTX/kg) effectively suppressed tumor growth compared to that observed in the control group (58). Different biologically important specific aptides have been also screened by phage-display. In 2013, Sangyong Jon et al. prepared HER2-specific-aptide-conjugated magneto-nanoclusters for cancer imaging as well as targeted therapy (59). Radiolabeling of aptides whether directly or by bifunctional chelating agents (BFCA) is a promising method for targeted cancer imaging intermediation (Figure 5).

Conclusion

Aptides are suitable candidates for tumor imaging and therapy, because they are small, high-affinity peptides with affinities in the nanomolar range with slow dissociation rates. In addition unlike antibodies or proteins, aptides are amenable to site-specific conjugation with variety of molecules like anticancer drugs for targeted therapy and biopharmaceutical applications without immunogenicity and imaging techniques during peptide synthesis, as expanding the range of potential applications. Altogether, the potential applications of novel aptide technology span the full range of biopharmaceutical applications, from biological research and diagnostics to therapeutics, including the direct development of peptide drugs.

In this mini review, we deduce that each plot has some advantages as well as also disadvantages. Even the integration of two or more delivery systems to improve the defects causes new disabilities. Challenges in targeted drug delivery in cancer diagnosis and treatment have not been removed so far.

Author Contribution

MM contributed to researching data and writing the draft, RF editing the manuscript and SN making study design, review, revise and editing the manuscript. All authors read and approved the final manuscript.

References


3. Chopra D. Radiolabelled Nanoparticles for Diagnosis and Treatment of Cancer: INTECH Open Access Publisher 2010: pp225-240


